Brokerages predict that Nightstar Therapeutics PLC (NASDAQ:NITE) will post ($0.34) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Nightstar Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.27) and the lowest estimate coming in at ($0.40). The firm is scheduled to issue its next quarterly earnings results on Tuesday, April 2nd.

On average, analysts expect that Nightstar Therapeutics will report full-year earnings of ($1.45) per share for the current financial year, with EPS estimates ranging from ($1.77) to ($1.25). For the next year, analysts forecast that the company will post earnings of ($1.53) per share, with EPS estimates ranging from ($1.93) to ($1.27). Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Nightstar Therapeutics.

NITE has been the subject of several research analyst reports. Barclays initiated coverage on Nightstar Therapeutics in a research note on Monday, December 17th. They issued an “overweight” rating and a $28.00 price objective for the company. Zacks Investment Research upgraded Nightstar Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, November 15th. UBS Group initiated coverage on Nightstar Therapeutics in a research note on Friday, January 4th. They issued a “buy” rating and a $21.00 price objective for the company. Cantor Fitzgerald restated a “buy” rating and issued a $42.00 price objective on shares of Nightstar Therapeutics in a research note on Thursday, January 31st. Finally, ValuEngine upgraded Nightstar Therapeutics from a “hold” rating to a “buy” rating in a research note on Thursday. Eleven equities research analysts have rated the stock with a buy rating, Nightstar Therapeutics has an average rating of “Buy” and an average target price of $31.00.

Shares of NASDAQ:NITE traded up $0.36 during trading on Friday, hitting $15.10. The stock had a trading volume of 29,535 shares, compared to its average volume of 51,194. Nightstar Therapeutics has a 12-month low of $9.59 and a 12-month high of $29.55. The stock has a market cap of $424.31 million, a price-to-earnings ratio of -9.26 and a beta of 3.15.

In related news, insider Gregory Scott Robinson sold 14,764 shares of Nightstar Therapeutics stock in a transaction that occurred on Wednesday, January 2nd. The stock was sold at an average price of $11.15, for a total transaction of $164,618.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO David A. Fellows sold 8,733 shares of Nightstar Therapeutics stock in a transaction that occurred on Monday, January 7th. The shares were sold at an average price of $12.98, for a total value of $113,354.34. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 24,328 shares of company stock valued at $291,734.

A number of hedge funds have recently made changes to their positions in NITE. Bank of America Corp DE purchased a new position in Nightstar Therapeutics during the second quarter valued at approximately $132,000. Harel Insurance Investments & Financial Services Ltd. purchased a new position in Nightstar Therapeutics during the third quarter valued at approximately $169,000. Janney Montgomery Scott LLC purchased a new position in Nightstar Therapeutics during the third quarter valued at approximately $204,000. JPMorgan Chase & Co. purchased a new position in Nightstar Therapeutics during the third quarter valued at approximately $214,000. Finally, Monashee Investment Management LLC purchased a new stake in shares of Nightstar Therapeutics in the third quarter valued at approximately $1,430,000. Institutional investors own 37.66% of the company’s stock.

About Nightstar Therapeutics

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.

Featured Article: Roth IRA

Get a free copy of the Zacks research report on Nightstar Therapeutics (NITE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Nightstar Therapeutics (NASDAQ:NITE)

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.